🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/03/2022 32,49 34,98 32,18 33,03 +0,82% 8,60% 497.000
07/03/2022 33,85 33,85 32,02 32,76 -3,31% 5,41% 694.100
04/03/2022 35,67 36,84 33,14 33,88 -6,36% 10,37% 809.400
03/03/2022 37,12 37,42 35,14 36,18 -1,23% 6,14% 1.481.800
02/03/2022 37,27 37,29 36,17 36,63 -2,48% 2,99% 435.000
01/03/2022 37,47 38,63 36,43 37,56 +0,97% 5,87% 610.400
28/02/2022 36,14 37,36 36,06 37,20 +1,92% 3,60% 828.200
25/02/2022 35,50 37,55 34,93 36,50 +2,56% 7,38% 892.700
24/02/2022 28,72 35,78 28,72 35,59 +18,59% 24,58% 1.274.900
23/02/2022 30,30 30,77 29,75 30,01 +0,50% 3,37% 581.100
22/02/2022 30,04 31,07 29,65 29,86 -2,07% 4,73% 661.000
18/02/2022 29,09 30,82 29,09 30,49 +3,78% 5,95% 646.600
17/02/2022 28,77 30,11 28,73 29,38 +1,59% 4,81% 946.100
16/02/2022 29,29 29,96 28,69 28,92 -2,63% 4,32% 560.200
15/02/2022 29,28 30,37 29,28 29,70 +2,70% 3,72% 521.500
14/02/2022 29,65 29,92 28,76 28,92 -1,36% 3,91% 461.700
11/02/2022 30,69 31,08 29,10 29,32 -4,59% 6,45% 539.500
10/02/2022 31,50 33,39 30,14 30,73 -4,71% 10,30% 644.800
09/02/2022 30,57 32,31 30,57 32,25 +6,44% 5,69% 635.100
08/02/2022 30,06 30,49 29,42 30,30 +0,03% 3,58% 301.400
07/02/2022 29,29 30,88 29,29 30,29 +3,03% 5,41% 395.600
04/02/2022 29,18 29,79 29,07 29,40 +0,41% 2,47% 608.300
03/02/2022 29,07 29,91 28,90 29,28 -2,56% 3,47% 513.500
02/02/2022 31,09 31,36 29,86 30,05 -4,51% 4,82% 463.700
01/02/2022 31,10 31,56 30,34 31,47 +2,18% 3,92% 609.800
31/01/2022 29,72 31,06 29,44 30,80 +3,53% 5,47% 531.700
28/01/2022 29,16 29,78 28,09 29,75 +1,61% 5,80% 487.200
27/01/2022 31,31 31,31 29,08 29,28 -5,15% 7,12% 400.000
26/01/2022 31,11 33,40 30,42 30,87 +0,06% 9,58% 582.900
25/01/2022 31,04 31,46 29,97 30,85 -2,83% 4,82% 452.400